H Krum

Summary

Affiliation: Monash University
Country: Australia

Publications

  1. ncbi Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy
    Alex Tzanidis
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of MedicineEpidemiology and Preventive Medicine, Monash University Medical School, Prahran, Victoria, Australia
    Circ Res 93:246-53. 2003
  2. doi Telephone support to rural and remote patients with heart failure: the Chronic Heart Failure Assessment by Telephone (CHAT) study
    Henry Krum
    Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Vic, Australia
    Cardiovasc Ther 31:230-7. 2013
  3. doi A novel algorithm for individualized cardiac resynchronization therapy: rationale and design of the adaptive cardiac resynchronization therapy trial
    Henry Krum
    Department of Epidemiology and Preventive Medicine, Monash Centre of Cardiovascular Research and Education in Therapeutics, 89 Commercial Road, Melbourne, VIC 3004 Australia
    Am Heart J 163:747-752.e1. 2012
  4. ncbi Current modalities for invasive and non-invasive monitoring of volume status in heart failure
    Thomas G von Lueder
    Department of Epidemiology and Preventive Medicine, Alfred Hospital, Monash University, Melbourne, VIC 3004, Australia
    Heart 98:967-73. 2012
  5. ncbi New and emerging drug therapies for the management of acute heart failure
    H Krum
    Department of Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria, Australia
    Intern Med J 33:515-20. 2003
  6. ncbi A feeling in the waters: diagnosis of heart failure using urinary natriuretic peptides
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria, Australia
    Clin Sci (Lond) 106:111-2. 2004
  7. doi Beta-blockers should remain as first-line therapy in the management of hypertension
    H Krum
    Department of Epidemiology and Preventive Medicine, Monash Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Vic, Australia
    Int J Clin Pract 62:1137-41. 2008
  8. ncbi Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy
    H Krum
    National Health and Medical Research Council of Australia Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Alfred Hospital, Prahran, Victoria, Australia
    Diabet Med 20:708-12. 2003
  9. doi Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program
    Henry Krum
    Department of Epidemiology and Preventive Medicine, NHMRC Centre of Clinical Research Excellence in Therapeutics, Monash University, Alfred Hospital, Melbourne VIC 3004, Australia
    Eur J Heart Fail 11:542-50. 2009
  10. ncbi Demographics and concomitant disorders in heart failure
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia
    Lancet 362:147-58. 2003

Collaborators

Detail Information

Publications125 found, 100 shown here

  1. ncbi Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy
    Alex Tzanidis
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of MedicineEpidemiology and Preventive Medicine, Monash University Medical School, Prahran, Victoria, Australia
    Circ Res 93:246-53. 2003
    ....
  2. doi Telephone support to rural and remote patients with heart failure: the Chronic Heart Failure Assessment by Telephone (CHAT) study
    Henry Krum
    Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Vic, Australia
    Cardiovasc Ther 31:230-7. 2013
    ..Telephone support comprised an interactive telecommunication software tool (TeleWatch) with follow-up by trained cardiac nurses...
  3. doi A novel algorithm for individualized cardiac resynchronization therapy: rationale and design of the adaptive cardiac resynchronization therapy trial
    Henry Krum
    Department of Epidemiology and Preventive Medicine, Monash Centre of Cardiovascular Research and Education in Therapeutics, 89 Commercial Road, Melbourne, VIC 3004 Australia
    Am Heart J 163:747-752.e1. 2012
    ....
  4. ncbi Current modalities for invasive and non-invasive monitoring of volume status in heart failure
    Thomas G von Lueder
    Department of Epidemiology and Preventive Medicine, Alfred Hospital, Monash University, Melbourne, VIC 3004, Australia
    Heart 98:967-73. 2012
    ..The current evidence for volume status monitoring in HF using those novel management strategies is reviewed...
  5. ncbi New and emerging drug therapies for the management of acute heart failure
    H Krum
    Department of Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria, Australia
    Intern Med J 33:515-20. 2003
    ..This review will examine the key emerging therapies for acute heart failure, in light of available pathophysiological and clinical evidence...
  6. ncbi A feeling in the waters: diagnosis of heart failure using urinary natriuretic peptides
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria, Australia
    Clin Sci (Lond) 106:111-2. 2004
    ..Further investigation is required and eagerly awaited...
  7. doi Beta-blockers should remain as first-line therapy in the management of hypertension
    H Krum
    Department of Epidemiology and Preventive Medicine, Monash Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Vic, Australia
    Int J Clin Pract 62:1137-41. 2008
  8. ncbi Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy
    H Krum
    National Health and Medical Research Council of Australia Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Alfred Hospital, Prahran, Victoria, Australia
    Diabet Med 20:708-12. 2003
    ....
  9. doi Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program
    Henry Krum
    Department of Epidemiology and Preventive Medicine, NHMRC Centre of Clinical Research Excellence in Therapeutics, Monash University, Alfred Hospital, Melbourne VIC 3004, Australia
    Eur J Heart Fail 11:542-50. 2009
    ..Non-steroidal anti-inflammatory drugs have been associated with increased risk of congestive heart failure (CHF). We aimed to assess the impact of treatment with etoricoxib or diclofenac on risk of CHF relative to baseline risk factors...
  10. ncbi Demographics and concomitant disorders in heart failure
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia
    Lancet 362:147-58. 2003
    ..Similarly, because chronic heart failure is commonly an endpoint in intervention trials of both hypertension and diabetes, such studies afford important information on the prevention of chronic heart failure in these common diseases...
  11. ncbi Expanding indications for pacing in chronic heart failure
    Henry Krum
    Med J Aust 190:470-1. 2009
    ..Do you have patients who could benefit from therapeutic pacing and defibrillator devices?..
  12. ncbi Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease
    Henry Krum
    NH and MRC Centre of Clinical Research Excellence in Therapeutics, Department of Medicine, Monash University, Alfred Hospital, Melbourne, Victoria 3004, Australia
    Curr Opin Investig Drugs 4:298-302. 2003
    ..The complexity of the endothelin system and its diverse roles in multiple disease states will ensure its position as a target for drug development...
  13. ncbi New developments in the pharmacological treatment of chronic heart failure
    Henry Krum
    Department of Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria 3004, Australia
    Expert Opin Investig Drugs 12:751-7. 2003
    ..That the mortality and morbidity of patients with chronic heart failure remain unacceptably high makes the ongoing commitment to exploration of new drug therapies for the condition critical...
  14. ncbi Beta-blockers in chronic heart failure: what have we learned? What do we still need to know?
    Henry Krum
    National Health and Medical Research Council of Australia Centre of Clinical Research Excellence in Therapeutics, Monash University, Alfred Hospital, Victoria 3004, Melbourne, Australia
    Curr Opin Pharmacol 3:168-74. 2003
    ..The impact of genetic polymorphisms on the response to beta-blocker therapy, as well as interaction of these agents with future heart failure therapies, requires extensive investigation...
  15. ncbi Recent advances in the management of chronic heart failure
    Henry Krum
    Clinical Pharmacology Unit, Department of Epidemiology and Preventive Medicine, Monash University Medical School, Alfred Hospital, Melbourne, VIC 3004
    Aust Fam Physician 32:39-43. 2003
    ....
  16. ncbi Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study
    Henry Krum
    NHMRC Centre for Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, 3rd Floor, Burnet Tower, AMREP Precinct, Commercial Road, Melbourne VIC 3004, Australia
    Eur J Heart Fail 8:302-7. 2006
    ..However, there remains concern regarding tolerability of these agents in the elderly, which has contributed to the limited uptake of these agents in clinical practice...
  17. ncbi Bush telegraph. Improving outcomes for rural and remote patients with chronic heart failure
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Departments of Epidemiology and Preventive Medicine and Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Victoria
    Aust Fam Physician 33:76-7. 2004
  18. ncbi Therapeutic potential of blockade of the urotensin II system in systemic hypertension
    Henry Krum
    Department of Epidemiology and Preventive Medicine, Monash University Alfred Hospital, 89 Commercial Road, Melbourne, VIC 3004, Australia
    Curr Hypertens Rep 9:53-8. 2007
    ..Early preclinical and clinical studies report potential beneficial effects in renal disease, heart failure, and diabetes, although effects on blood pressure have been equivocal...
  19. ncbi Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne 3004, Australia
    Eur Heart J 26:2154-8. 2005
    ..The magnitude of the prognostic benefit of BBs in the absence of ACE-I or ARB has not as yet been determined...
  20. ncbi Could risk stratification aid the treatment of patients with acute decompensated heart failure?
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Alfred Hospital, Monash University, Victoria, Australia
    Nat Clin Pract Cardiovasc Med 2:334-5. 2005
  21. ncbi Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension
    Henry Krum
    National Health and Medical Research Council of Australia, Centre of Clinical Research Excellence in Therapeutics, Monash University, Melbourne, VIC 3004, Australia
    Am J Physiol Heart Circ Physiol 290:H1706-12. 2006
    ..We conclude that sympathetic nervous inhibition is not a major component of the blood pressure-lowering action of ARBs in essential hypertension...
  22. ncbi Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study
    Henry Krum
    Monash University, Melbourne, Australia
    Am Heart J 151:55-61. 2006
    ..We therefore examined this question in the COPERNICUS study of 2289 patients with severe CHF receiving the beta1-beta2/alpha1 blocker carvedilol compared with placebo...
  23. ncbi Blood pressure effects of COX-2 inhibitors
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
    J Cardiovasc Pharmacol 47:S43-8. 2006
    ..Such studies have recently been announced and will commence soon...
  24. ncbi Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction? A multicentre study
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University and Alfred Hospital, Melbourne, Victoria, Australia
    Med J Aust 185:191-4. 2006
    ..To evaluate the use of cardiovascular medications in patients with and without heart failure after myocardial infarction (MI)...
  25. ncbi Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
    Cardiology 108:28-34. 2007
    ....
  26. ncbi Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT
    Henry Krum
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Monash University, Melbourne, Australia
    Int J Cardiol 119:48-53. 2007
    ..To address this, we retrospectively analyzed the Valsartan Heart Failure Trial (Val-HeFT) database to determine outcomes in CHF patients according to statin use at baseline...
  27. ncbi Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders
    Henry Krum
    NHMRC Centre of Clinical Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Alfred Hospital, Central and Eastern Clinical School, Melbourne, Victoria 3004, Australia
    J Hypertens 25:25-35. 2007
    ..Finally, ACE2 augmentation, antisense gene strategies, and vaccination against the renin-angiotensin system should still be considered experimental, but have significant appeal as additional approaches to the blockade of this system...
  28. ncbi Eplerenone in the treatment of chronic heart failure
    Henry Krum
    Department of Epidemiology and Preventive Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria 3004, Australia
    Expert Rev Cardiovasc Ther 2:315-20. 2004
    ..Due to the fact that eplerenone is a selective aldosterone receptor antagonist, it does not cause troublesome hormonal side effects. This is an important feature of the drug that is likely to help maintain compliance...
  29. ncbi Cardiovascular effects of selective cyclooxygenase-2 inhibitors
    Henry Krum
    NHMRC Centre of Clinical Excellence in Therapeutics, Departments of Medicine, Epidemiology and Preventive Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria 3004, Australia
    Expert Rev Cardiovasc Ther 2:265-70. 2004
    ..Therefore, what is clear in this situation is the urgent need for randomized clinical trials designed specifically to examine the impact of selective cyclooxygenase-2 inhibitors on cardiovascular risk...
  30. ncbi Tolerability of carvedilol in heart failure: clinical trials experience
    Henry Krum
    Department of Medicine and Epidemiology, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Australia
    Am J Cardiol 93:58B-63B. 2004
    ..Thus, in contrast to widely held perceptions about tolerability of beta-blockade in heart failure, carvedilol appears to be an extremely well-tolerated agent, even during initiation and in the most advanced patients...
  31. doi Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study
    Henry Krum
    Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, Australia
    J Hypertens 27:886-93. 2009
    ..To evaluate the hypertensive effects of etoricoxib and diclofenac relative to baseline hypertension risk factors in arthritis patients...
  32. ncbi Beta-blockers in heart failure. The 'new wave' of clinical trials
    H Krum
    Dept of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Prahran, Victoria, Australia
    Drugs 58:203-10. 1999
    ..Despite this, further questions remain regarding the use of these agents in CHF, including their role in the extreme elderly, in patients with diabetes mellitus and in patients with renal impairment...
  33. ncbi Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study
    Henry Krum
    Dept of Medicine and Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, 3181 Australia
    JAMA 289:712-8. 2003
    ..Beta-blockers remain underused despite their established utility for improving outcome in heart failure. Concerns that initiation of treatment produces few immediate benefits and may have important risks may be deterring widespread use...
  34. ncbi Guidelines for management of patients with chronic heart failure in Australia
    H Krum
    Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Vic
    Med J Aust 174:459-66. 2001
    ..Spironolactone, angiotensin II receptor antagonists and digoxin may be useful in some patients. Surgical approaches in highly selected patients may include myocardial revascularisation, insertion of devices and cardiac transplantation...
  35. ncbi Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure
    H Krum
    Clinical Pharmacology Unit, Dept of Epidemiology and Preventive Medicine Department of Medicine, Monash University Alfred Hospital, Prahran, Victoria, Australia
    Heart Fail Rev 6:341-52. 2001
    ....
  36. ncbi Differentiation in the angiotensin II receptor 1 blocker class on autonomic function
    H Krum
    Clinical Pharmacology Unit, Department of Epidemiology and Preventive Medicine Department of Medicine, Monash University Alfred Hospital, Commercial Road, Prahran, Victoria 3181, Australia
    Curr Hypertens Rep 3:S17-23. 2001
    ....
  37. ncbi New and emerging drug treatments for hypertension
    H Krum
    Department of Clinical Pharmacology, Monash University Alfred Hospital, Prahran, Victoria
    Aust Fam Physician 27:235-7, 240-2. 1998
    ..Furthermore, morbidity and mortality benefits have not been established with commonly used agents such as ACE inhibitors and calcium channel blockers...
  38. ncbi New and emerging pharmacological strategies in the management of chronic heart failure
    H Krum
    Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Prahran, Victoria, Australia
    Curr Opin Pharmacol 1:126-33. 2001
    ..g. agents that block tumour necrosis factor-alpha activity), agents that favourably modulate extracellular matrix (e.g. matrix metalloprotease inhibitors) and agents that augment natriuretic peptides...
  39. ncbi Statins and chronic heart failure: do we need a large-scale outcome trial?
    Henry Krum
    Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Prahan Victoria, Australia
    J Am Coll Cardiol 39:1567-73. 2002
    ..These uncertainties indicate the need for a definitive outcome trial to assess the efficacy and safety of statins in CHF, despite their current widespread, non-evidence based use in this population...
  40. ncbi Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients
    Henry Krum
    Clinical Pharmacology Unit, Monash University, Alfred Hospital, Prahran, Victoria, Australia
    Hypertension 40:117-23. 2002
    ..Selective aldosterone blockade with eplerenone, therefore, may be useful add-on therapy in hypertensive patients inadequately controlled on ACE inhibitor or ARB alone...
  41. doi Novel procedure- and device-based strategies in the management of systemic hypertension
    Henry Krum
    Monash Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University Alfred Hospital, Melbourne, VIC 3004, Australia
    Eur Heart J 32:537-44. 2011
    ..Novel procedure- and device-based strategies to control hypertension include renal sympathetic denervation and baroreflex sensitization. These two techniques will be the focus of the present review...
  42. doi Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials
    Henry Krum
    Monash University Alfred Hospital, Melbourne, Victoria 3004, Australia
    Cardiovasc Ther 28:124-32. 2010
    ....
  43. doi Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context
    Henry Krum
    Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
    Clin Cardiol 33:536-41. 2010
    ..Copyright © 2010 Wiley Periodicals, Inc.The authors have no funding, financial relationships, or conflicts of interest to disclose...
  44. doi Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOS
    Henry Krum
    Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Alfred Hospital, Melbourne VIC 3004, Australia
    Eur J Heart Fail 13:107-14. 2011
    ..Perspective The ATMOSPHERE study will definitively determine the role of a DRI strategy additional to or as an alternative to conventional RAAS blockade in patients with chronic systolic HF...
  45. ncbi Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1)
    A Tzanidis
    Department of Medicine Epidemiology and Preventive Medicine, Monash University Medical School, Alfred Hospital, Commercial Road, Prahran 3181, Victoria, Australia
    J Mol Cell Cardiol 33:969-81. 2001
    ..These data demonstrate that combined AngII and ET receptor blockade has beneficial effects on myocardial fibrogenesis over individual treatments during adverse cardiac remodeling early post-MI...
  46. doi Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction
    A R Kompa
    Department of Epidemiology and Preventive Medicine, Alfred Hospital, Central and Eastern Clinical School, Monash University, Commercial Rd, Prahran, Victoria, Australia
    J Pharmacol Exp Ther 325:741-50. 2008
    ..Continuous but not short-term p38 MAPK blockade attenuates post-MI remodeling, which is associated with functional benefits on the myocardium...
  47. pmc Barriers to achieving blood pressure treatment targets in elderly hypertensive individuals
    E K Chowdhury
    Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
    J Hum Hypertens 27:545-51. 2013
    ..These findings identify clinical markers that can be targeted for intervention, but also demographic factors related to service delivery, which may provide further opportunity for achieving better BP control in hypertensive elderly. ..
  48. ncbi Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?
    Tai Juan Aw
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia
    J Hypertens 24:1979-84. 2006
    ..Rofecoxib is uniquely metabolized by cytosol reductase and may compete with aldosterone for metabolism. We hypothesized that the effect of rofecoxib on BP may be due to an increase in aldosterone levels...
  49. ncbi Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials
    F L Rosenfeldt
    Cardiac Surgical Research Unit, Alfred Hospital, Melbourne, Australia
    J Hum Hypertens 21:297-306. 2007
    ..3 (8.4-12.3, P<0.001) mm Hg. We conclude that coenzyme Q10 has the potential in hypertensive patients to lower systolic blood pressure by up to 17 mm Hg and diastolic blood pressure by up to 10 mm Hg without significant side effects...
  50. ncbi Drug administration in patients with diabetes mellitus. Safety considerations
    R E Gilbert
    Melbourne University Department of Medicine, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
    Drug Saf 18:441-55. 1998
    ..Although caution should also be used with beta-blocker therapy in patients with diabetes mellitus, current evidence suggests that, like ACE inhibitors, these drugs may be particularly useful in this patient group...
  51. doi Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction
    Arintaya Phrommintikul
    Dept of Epidemiology and Preventive Medicine, Monash University, Melbourne VIC 3004, Australia
    Am J Physiol Heart Circ Physiol 294:H1804-14. 2008
    ..7%; P < 0.05), GSK 3 (23.8%; P < 0.01), and ramipril (35.5%; P < 0.01) treatment. These results suggest that ROCK inhibition improves LV geometry and reduces collagen deposition accompanied by improved diastolic function in POH...
  52. pmc Baseline predictors of tolerability to carvedilol in patients with chronic heart failure
    H Krum
    Clinical Pharmacology Unit, Department of Epidemiology and Preventive Medicine, Department of Medicine, Monash University Alfred Hospital, Prahran, Victoria
    Heart 84:615-9. 2000
    ..To determine baseline predictors of tolerance to the alpha/beta blocker carvedilol in everyday clinical practice...
  53. doi Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classes
    D J Campbell
    St Vincent s Institute of Medical Research, Melbourne, Victoria, Australia
    Intern Med J 43:137-43. 2013
    ....
  54. ncbi PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994-1998
    M R Nelson
    Department of Epidemiology and Preventive Medicine, Monash Medical School, Alfred Hospital, Melbourne, Vic
    Med J Aust 174:565-8. 2001
    ....
  55. ncbi Comparative effects of mibefradil and nifedipine gastrointestinal transport system on autonomic function in patients with mild to moderate essential hypertension
    A M Pellizzer
    Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Prahran, Victoria, Australia
    J Hypertens 19:279-85. 2001
    ..71 +/- 0.02 versus 0.74 +/- 0.03, P = 0.046). CONCLUSION: No differences existed between effect of L- and T-type CCBs on SNSA and BRS. However, T-type CCBs increased PSNA, independent of achieved changes in heart rate...
  56. ncbi Eplerenone (GD Searle & Co)
    J Martin
    Monash University, Alfred Hospital, Prahran, Victoria, Australia
    Curr Opin Investig Drugs 2:521-4. 2001
    ..The trial will evaluate whether eplerenone can reduce the rate of mortality in patients who have recently had a heart attack that resulted in a diagnosis of heart failure 13535481...
  57. doi Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension
    Markus P Schlaich
    Neurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute, St Kilda Road Central, Melbourne, Victoria 8008, Australia
    Curr Hypertens Rep 12:39-46. 2010
    ..Accordingly, renal sympathetic nerve ablation appears to be a logical therapeutic approach for the treatment of hypertension. Recent reports on a novel catheter-based renal nerve ablation procedure reviewed in this article are promising...
  58. ncbi Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
    Laurence G Howes
    Department of Clinical Pharmacology, St George Hospital, University of New South Wales, Kogarah, New South Wales, Australia
    Drug Saf 25:829-35. 2002
    ....
  59. ncbi Coenzyme Q10 in cardiovascular disease
    Salvatore Pepe
    CJOB Department of Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia
    Mitochondrion 7:S154-67. 2007
    ..3. Presently, due to the notable absence of clinically significant side effects and likely therapeutic benefit, CoQ(10) can be considered a safe adjunct to standard therapies in cardiovascular disease...
  60. doi Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction
    K A Connelly
    Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael s Hospital and University of Toronto, Toronto, Canada
    Cardiovasc Ther 31:84-91. 2013
    ..We sought to determine the effectiveness of this strategy after myocardial infarction (MI) in the setting of preexisting hypertension, a common premorbid condition in patients with ischemic heart disease...
  61. ncbi Chronic heart failure in Australian general practice. The Cardiac Awareness Survey and Evaluation (CASE) Study
    H Krum
    Alfred Hospital, Melbourne, Vic
    Med J Aust 174:439-44. 2001
    ..Of 100 patients aged 60 years and over presenting to their GP, two new cases of CHF will be detected using a simple clinical algorithm in conjunction with appropriate diagnostic tests. ACE inhibitors appear to be underutilised...
  62. doi Five-minute heart rate variability can predict obstructive angiographic coronary disease
    D Kotecha
    Monash Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia
    Heart 98:395-401. 2012
    ..Five-minute heart rate variability (HRV) is a non-invasive marker for autonomic control of the vasculature, which this study hypothesised could risk-stratify cardiac patients and reduce unnecessary angiograms...
  63. ncbi Effect of a highly selective endothelin-converting enzyme inhibitor on cardiac remodeling in rats after myocardial infarction
    P Martin
    Clinical Pharmacology Unit, Monash University, Melbourne, Australia
    J Cardiovasc Pharmacol 36:S367-70. 2000
    ..However, longer-term studies are needed fully to assess the therapeutic potential of ECE inhibitor post-MI and in heart failure...
  64. ncbi Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat
    K A Connelly
    University of Melbourne Department of Medicine, St Vincent s Hospital, Victoria, Australia
    Cardiovasc Res 76:280-91. 2007
    ....
  65. ncbi Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats
    Lavinia Tran
    Department of Epidemiology and Preventive Medicine, National Health Medical Research Council Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia
    Am J Physiol Heart Circ Physiol 298:H608-13. 2010
    ..Chronic U-II infusion causes diastolic dysfunction, caused by fibrosis of the LV. The in vitro data suggest that this may be in part occurring via a ROCK-dependent pathway...
  66. doi Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers
    Genevieve Flannery
    Clinical Pharmacology Unit, Alfred Hospital, Melbourne, Australia
    Am J Cardiol 101:865-9. 2008
    ..Therefore, the magnitude of HR reduction may be more important than the achievement of target dose in beta-blocker treatment of systolic CHF...
  67. ncbi Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials
    Steven Joseph Haas
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, Australia
    Am Heart J 146:848-53. 2003
    ....
  68. ncbi Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures
    K A Connelly
    Dept of Medicine, University of Melbourne, St Vincent s Hospital, Victoria, Australia
    Am J Physiol Heart Circ Physiol 290:H1699-705. 2006
    ..To accurately identify changes in systolic function, we suggest that a combination of echocardiography with assessment of load-insensitive measures be used routinely...
  69. ncbi Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension
    E Zomer
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventative Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, Australia
    Clin Exp Pharmacol Physiol 35:1147-50. 2008
    ..9 +/- 411.3 vs 1984.4 +/- 410.7 AFUs, respectively). In conclusion, UII causes net vasoconstriction in DM. The UII-induced increases in peripheral vascular tone may contribute to DM-related cardiovascular complications...
  70. ncbi A systematic review of predictors of maintenance of normotension after withdrawal of antihypertensive drugs
    M Nelson
    Department of Epidemiology and Preventive Medicine, Monash Medical School, Alfred Hospital, Prahran, Australia
    Am J Hypertens 14:98-105. 2001
    ..Once therapy has been started, treating physicians have difficulty in selecting patients for withdrawal and have concerns regarding patient safety and their own legal liability...
  71. ncbi Pressor dose responses and baroreflex sensitivity in quadriplegic spinal cord injury patients
    H Krum
    Department of Clinical Pharmacology, Austin Hospital, Heidelberg, Victoria, Australia
    J Hypertens 10:245-50. 1992
    ..To assess the relative contribution of impaired baroreceptor reflexes and enhanced cardiovascular reactivity to the exaggerated blood pressure rises which occur in quadriplegic spinal cord injury patients with automatic hyperreflexia...
  72. ncbi The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations
    R E Gilbert
    University of Melbourne, Department of Medicine St Vincent s Hospital, Victoria, Australia
    Diabet Med 20:607-21. 2003
    ....
  73. pmc Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian national blood pressure study cohort
    Mark R Nelson
    Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Prahran 3181, Australia
    BMJ 325:815. 2002
    ..To identify simple long term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in elderly patients in general practice...
  74. ncbi Altered sympathetic and parasympathetic activity in lung transplantation patients at rest and following autonomic perturbation
    Amy Berakis
    Clinical Pharmacology Unit, Department of Epidemiology and Preventive Medicine, Monash University Medical School, Alfred Hospital, Prahran, Victoria 3181, Australia
    Chest 122:1192-9. 2002
    ..To investigate the nature and extent of the alteration in autonomic function following heterotopic lung transplantation...
  75. ncbi Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure
    Henry Krum
    Monash University, Alfred Hospital, Melbourne, Victoria, Australia
    J Card Fail 13:1-7. 2007
    ..However, chronic heart failure (CHF) patients were often excluded in such trials. Statins possess pharmacologic properties (independent of cholesterol lowering) that may be beneficial on ventricular remodeling in such patients...
  76. ncbi Aldosterone receptor antagonists for hypertension: what do they offer?
    Danny Liew
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria, Australia
    Drugs 63:1963-72. 2003
    ..Perhaps most notably, eplerenone was generally well tolerated, and did not cause the antiandrogenic and progestational adverse effects commonly observed with spironolactone...
  77. ncbi Eplerenone. Pharmacia
    Danny Liew
    National Health and Medical Research Council, Department of Epidemiology, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria 3004, Australia
    Curr Opin Investig Drugs 4:316-22. 2003
    ..The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on positive results from a phase III clinical trial...
  78. ncbi The role of aldosterone receptor blockade in the management of cardiovascular disease
    Danny Liew
    Department of Medicine, Monash University Medical School, Alfred Hospital, Melbourne, Victoria, Australia
    Curr Opin Investig Drugs 3:1468-73. 2002
    ..Importantly, eplerenone does not appear to cause the hormonal side effects observed with spironolactone...
  79. ncbi Factors influencing family physician adherence to hypertension treatment guideline recommendations on the initiation of pharmacotherapy: questionnaire survey
    Mark R Nelson
    Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Prahran, Australia
    Am J Cardiovasc Drugs 3:437-41. 2003
    ....
  80. ncbi Fibrosis as a therapeutic target post-myocardial infarction
    Fiona See
    National Health and Medical Research Council of Australia Centre of Clinical Research Excellence in Therapeutics, Monash University, Alfred Hospital, Melbourne Victoria 3004, Australia
    Curr Pharm Des 11:477-87. 2005
    ..Furthermore, specific anti-fibrotic drugs have been developed and are currently being explored for these and other cardiac conditions where pathological ECM deposition is felt to be contributory to disease progression...
  81. ncbi Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE)
    Mark Nelson
    Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Prahan, Victoria, Australia
    Drugs Aging 20:897-903. 2003
    ..This sample size has a power of 87% to detect a 15% reduction in primary events in the aspirin group, with an anticipated combined primary event rate of 20 per 1000 patient years...
  82. ncbi Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003
    Steven J Haas
    Department of Epidemiology and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Alfred Hospital, Melbourne, Victoria, Australia
    Drug Saf 30:47-57. 2007
    ..Clozapine is used specifically in patients for whom previous therapy was inadequate or not tolerated, and is the only antipsychotic agent associated with the development of myocarditis...
  83. doi Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy
    Andrew R Kompa
    Department of Medicine, Monash University, Alfred Hospital, Victoria, Australia
    Peptides 31:1523-30. 2010
    ..We hypothesize that other neurohumoral pathways may have a greater involvement in the pathogenesis of this model. Targeting the UII system appears to be insufficient to observe a beneficial outcome...
  84. doi Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis
    Clara C Chan
    Department of Clinical Pharmacology, Alfred Hospital, Australia
    J Hypertens 27:2332-41. 2009
    ....
  85. ncbi In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling
    Jennifer Martin
    National Health and Medical Research Council of Australia Centre for Clincial Research and Excellence in Therapeutics, Epidemiology and Preventive Medicine, Monash University Alfred Hospital, Melbourne, Victoria, Australia
    Clin Exp Pharmacol Physiol 32:697-701. 2005
    ..4. Atorvastatin appears to directly inhibit collagen production by cardiac fibroblasts. This antifibrotic action may contribute to the antiremodelling effect of statins...
  86. ncbi Chronic heart failure--optimising care in general practice
    Leon Piterman
    School of Primary Health Care, Monash University, Victoria, Australia
    Aust Fam Physician 34:547-53. 2005
    ..In Australia, over 300 000 people are affected by CHF. Quality general practice forms the cornerstone for early diagnosis and evidence based integrated care...
  87. ncbi Pilot study of the prevalence, outcomes and detection of occult hypoperfusion in trauma patients
    Ogilvie Thom
    Box Hill Hospital, Nelson Road, Box Hill 3128, Australia
    Emerg Med J 27:470-2. 2010
    ..Occult hypoperfusion (OH) is defined as hypoperfusion in the presence of normal vital signs. It is associated with increased length of stay (LOS) and increased mortality...
  88. ncbi Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure
    Tai Juan Aw
    Department of Clinical Pharmacology, Monash University, Alfred Hospital, Melbourne, Victoria 3004, Australia
    Arch Intern Med 165:490-6. 2005
    ..We therefore performed a meta-analysis comparing the effects of coxibs with placebo, nonselective NSAIDs, and each other on BP elevation and hypertension...
  89. ncbi Should patients with chronic heart failure be treated with "statins"?
    Emma Ashton
    NHMRC Centre of Clinical Research Excellence, Department of Epidemiology and Preventive Medicine, Monash University, Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria 3004, Australia
    Heart Fail Monit 3:82-6. 2003
    ..The importance of such a trial is further highlighted by the already commonplace usage of statins amongst patients with CHF...
  90. doi Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
    Henry Krum
    Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
    Lancet 373:1275-81. 2009
    ....
  91. ncbi Using adult stem cells to treat heart failure--fact or fiction?
    Hendrik Zimmet
    Monash Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia
    Heart Lung Circ 17:S48-54. 2008
    ....
  92. ncbi Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT
    Henry Krum
    Monash University Medical School, Alfred Hospital, Melbourne, Australia
    Eur J Heart Fail 6:937-45. 2004
    ..To investigate the effect of valsartan in the Valsartan-Heart Failure Trial (Val-HeFT) when added to angiotensin-converting enzyme inhibitor (ACEi) alone in patients with heart failure (HF)...
  93. ncbi Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease
    Jennifer Martin
    Clinical Pharmacology Unit, Monash Medical School The Alfred Hospital, Commercial Road, Prahan, VIC 3181, Australia
    Pharmacol Res 46:203-12. 2002
    ..This article provides an overview of the place of ARBs in general and of the ARB valsartan in particular, and draws comparisons to ACE inhibitors in the treatment of cardiovascular diseases...
  94. ncbi Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure
    Andrew E Ajani
    Department of Cardiology, Royal Melbourne Hospital, and Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
    Cardiovasc Revasc Med 7:234-6. 2006
    ..The evidence supporting this agent will be briefly reviewed, followed by a discussion on the clinical implications of aldosterone antagonists in this clinical setting...
  95. ncbi Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?
    Jennifer Martin
    Clinical Pharmacology Unit, Monash Medical School Alfred Hospital, Prahran, Victoria, Australia
    Drug Saf 26:13-21. 2003
    ..In particular, patients taking a CYP3A4-metabolised agent, e.g. atorvastatin, simvastatin and lovastatin, should not be started on a CYP3A4 inhibitor or inducer without close monitoring...
  96. doi Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study
    Emma Ashton
    Department of Health Science, Monash University, Frankston Vic 3119, Melbourne, Australia
    Int J Cardiol 146:404-7. 2011
    ..These agents may also possess additional properties, independent of effects on blood lipid levels, which may have an effect on cardiac remodeling. However, beneficial effects were not observed in the recent UNIVERSE trial...
  97. ncbi Resistance exercise training increases muscle strength, endurance, and blood flow in patients with chronic heart failure
    D L Hare
    Department of Cardiology, Austin and Repatriation Medical Centre, Melbourne, Australia
    Am J Cardiol 83:1674-7, A7. 1999
    ..There was also a significant increase in basal forearm blood flow following this form of exercise training...
  98. ncbi Improved outcomes from a comprehensive management system for heart failure
    D P Holst
    Cardiovascular Medicine, Heart Centre, Alfred Hospital, Commercial Road, Prahran, Melbourne, Victoria 3181, Australia
    Eur J Heart Fail 3:619-25. 2001
    ..We assessed the ability of a comprehensive management program (CMP) for CHF to reduce readmissions with secondary endpoints of improving quality of life, exercise capacity and targeted drug doses...
  99. doi Contemporary outcomes in women undergoing percutaneous coronary intervention for acute coronary syndromes
    Ali H Al-Fiadh
    Department of Cardiology, Austin Hospital, Victoria, Australia University of Melbourne, Australia
    Int J Cardiol 151:195-9. 2011
    ..Uncertainty remains as to whether females benefit as much as males from percutaneous coronary intervention (PCI) in the setting of an acute coronary syndrome (ACS)...
  100. ncbi Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease
    S M Killalea
    Clinical Pharmacology Unit, Department of Epidemiology and Preventive Medicine/Department of Medicine, Monash University, Prahran, Victoria, Australia
    Am J Cardiovasc Drugs 1:193-204. 2001
    ..Available evidence also suggests that the incidence of adverse events can be minimised, and the efficacy maintained, by keeping plasma perhexiline concentrations within a therapeutic range (150 to 600 micro g/L)..